You are using an older browser version. Please use a supported version for the best MSN experience.

Biogen halted trial could boost M&A activity, says analyst

Jared Holz, healthcare strategist at Jefferies, and Paul Matteis, co-head of biotech research at Stifel, discuss Biogen after shares of the company plunged on Thursday.

Recent Videos

Featured Partners

image beaconimage beaconimage beacon